Epstein AEDrugs and devices: contemporary practice in light of contemporary trials. J Cardiovasc Electrophysiol6:937, 1995
2.
Nacarelli GV , Shih T-T., Jalal S.Catheter ablation for the treatment of paroxysmal supraventricular tachycardia . J Cardiovasc Electrophysiol6:951, 1995
3.
TheCardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med321:406, 1989
4.
TheCardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med327:227, 1992
5.
Singh BN, Ahmed R.Class III antiarrhythmic drugs. Curr Opin Cardiol9:12, 1994
6.
Singh BNArrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J14:14, 1993
7.
Singh BNExpanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol6:887, 1995
8.
Singh BNChoice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Am J Cardiol72:114, 1993
9.
Colatsky TJ, Follmer CH, Starmer CFChannel specificity in antiarrhythmic drug action. Mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation82:2235, 1990
10.
Fermini B., Jurkiewiez NK, Jow B., et al. Use dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rcctifier potassium and L-type calcium currents. J Cardiovasc Pharmacol26:259, 1995
11.
Falk Rrh, Pollak A., Singh SN, et al, Intravenous ibutilide, a class III antiarrhythmic agent, for the termination or sustained atrial fibrillation or flutter. J Am Coll Cardiol29:385, 1997
12.
Ellenbogen KA, Stambler BS, Wood MA, ct al.Efficacy of intravenous ibutilidc for acute termination of atrial fibrillation and flutter: a dose-response study. J Am Coll Cardiol28:130, 1996
13.
Singh BNAcute conversion of atrial flutter and fibrillation: direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol29:391, 1997
14.
Holnloser S. , Klingenheben T., Singh BNAmiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Intern Med121:529, 1994
15.
Waldo AL, Camm AJ, Ruyter H., et al. Effects of d-sotalol on mortality in patients with left ventricular function after recent and remote myocardial infarction. Lancet348:7, 1996
16.
Nemeth M., Varro A., Virag L., Hala O., Thormahlen D., Papp JGFrequency-dependent cardiac electrophysiological effects of tedisamil: comparison with quinidine and sotalol. J Cardiovasc Pharmacol Therapeut3:271, 1997
17.
Tsuchihashi K., Curtis MJTedisamil possesses direct defibrillatory activity during myocardial ischemia and during reperfusion. Br J Pharmacol99:231 P, 1990
18.
Tsuchihashi K., Curtis MJChemical defibrillation in ischemia and reperfusion by selective blockade of the transient outward current (I 10). Circulation82:(Suppl III) III-452, 1991
19.
Dukes IDMorad M.Tedisamil inactivates transient outward K+ channels in rat and guinea pig ventricular myocytes. Am J Physiol257:H1746, 1989
20.
Dukes ID, Morad M.Tedisamil increases the rate of inactivation of the transient outward current in single rat ventricular myocytes. J Physiol ( Lond) 41:33, 1989
21.
Dukes ID, Cleeman L., Morad M.Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther254:560, 1990
22.
Friedrichs GS, Abreu JN, Cousins GR, Chi L., Borlak J., Lucchesi BRTedisamil attenuates ventricular fibrillation in a conscious canine model of suddent cardiac death . J Cardiovasc Pharmacol Therapeut1:313. 1996
23.
Grohs JG, Fischer G., Raberger G.Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exercise-induced myocardial ischemia. Eur J Pharmacol161:53, 1989
